RESUMEN
Soluble HLA (sHLA) are potential tumour markers released in order to counter immune surveillance. sHLA-class II is less known especially in acute lymphoblastic leukaemia (ALL). This study aimed to investigate soluble, surface and allelic expression of HLA Class II (sHLA-DR) in B-cell ALL patients and compare with soluble expression in normal individuals. A sandwich enzyme-linked immunosorbent assay (ELISA) was developed to measure soluble HLA-DRB1 in plasma. Flow cytometric analysis was performed to determine median fluorescence intensity in HLA-DR surface expression. HLA-DNA typing by polymerase chain reaction, sequence specific oligonucleotides, PCRSSO was performed to determine HLA-DRB1 type in ALL samples. Results showed sHLA-DRB1 (mean±SEM) was significantly increased (p=0.001) in plasma of ALL patients (0.260 ±0.057 µg/mL; n=30) compared to healthy controls (0.051 ± 0.007µg/mL; n=31) of Malay ethnicity. However, these levels did not correlate with percentage or median fluorescence intensity of HLA-DR expressed on leukemia blasts (CD19+CD34 ± CD45(lo)HLA-DR+) or in the normal B cell population (CD19+CD34- CD45(hi)HLA-DR+) of patients. No significant difference was observed in gender (male/female) or age (paediatric/adult). Only a trend in reduced sHLA was observed in patients carrying HLA-DR04. These results have to be validated with a larger number of samples.
Asunto(s)
Biomarcadores de Tumor/análisis , Cadenas HLA-DRB1/biosíntesis , Leucemia-Linfoma Linfoblástico de Células Precursoras B/inmunología , Adolescente , Adulto , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Humanos , Masculino , Reacción en Cadena de la Polimerasa , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patología , Adulto JovenRESUMEN
Recently, several types of immunotherapies have been shown to induce encouraging clinical results, though in a restricted number of patients. Consequently, there is a need to identify immune biomarkers to select patients who will benefit from such therapies. Such predictive biomarkers may be also used as surrogates for overall survival (OS). We have recently found correlations between immunologic parameters and clinical outcome in prostate cancer patients who had been vaccinated with a HER-2/neu hybrid polypeptide vaccine (AE37) and received one booster 6 months post-primary vaccinations. Herein, we aimed to expand these retrospective analyses by studying the predictive impact of HLA-A*24 and HLA-DRB1*11 alleles, which are expressed at high frequencies among responders in our vaccinated patients, for clinical and immunological responses to AE37 vaccination. Our data show an increased OS of patients expressing the HLA-DRB1*11 or HLA-A*24 alleles, or both. Vaccine-induced immunological responses, measured as interferon γ (IFN-γ) responses in vitro or delayed-type hypersensitivity reactions in vivo, were also higher in these patients and inversely correlated with suppressor elements. Preexisting (i.e., before vaccinations with AE37) levels of vaccine-specific IFN-γ immunity and plasma TGF-ß, among the HLA-A*24 and/or HLA-DRB1*11 positive patients, were strong indicators for immunological responses to AE37 treatment. These data suggest that HLA-DRB1*11 and HLA-A*24 are likely to be predictive factors for immunological and clinical responses to vaccination with AE37, though prospective validation in larger cohorts is needed.
Asunto(s)
Alelos , Vacunas contra el Cáncer/administración & dosificación , Antígeno HLA-A24/genética , Cadenas HLA-DRB1/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/terapia , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/inmunología , Vacunas contra el Cáncer/inmunología , Antígeno HLA-A24/biosíntesis , Antígeno HLA-A24/inmunología , Cadenas HLA-DRB1/biosíntesis , Cadenas HLA-DRB1/inmunología , Humanos , Masculino , Proyectos Piloto , Pronóstico , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/inmunología , Receptor ErbB-2/biosíntesis , Receptor ErbB-2/inmunología , Factor de Crecimiento Transformador beta/sangreRESUMEN
BACKGROUND: Allergic rhinitis (AR) is one of the most common allergic diseases. The results of recent studies of HLA-DRB1 suggest that HLA-DRB1 plays an important role in allergic disease. OBJECTIVE: The aim of the present study was to investigate the relationship between the H2-Eb1 (orthologous gene of human HLA-DRB1 in mice) gene and AR pathogenesis in AR mice. METHODS: Female 129/sv mice were sensitized with ovalbumin (OVA) to establish an AR mouse model. After successful induction, the nasal mucosa was fixed and stained for pathologic analysis, such as eosinophil (EOS) evaluation and mast cell infiltration etc. The Th1 and Th2 cytokines IFN-γ, IL-2, IL-4, IL-10 and the OVA-specific IgE levels were detected using the ELISA method. The H2-Eb1 and GATA-3 (GATA-binding protein-3) and T-bet (T-box expressed in T-cells) protein expression in the nasal mucosa were detected by the western blot or immune-histochemistry, immunofluorescence technique. The expression of H2-Eb1 mRNA in nasal mucosa was analyzed by quantitative real time PCR. RESULTS: Compared with the control group, the cilia layer in nasal mucosa of the experimental group was found to be partially desquamated; eosinophil (EOS) and mast cell infiltration was found in submucosal layer; serum OVA-IgE and IL-4, IL-10 levels were found to be significantly increased, together with a decrease of IFN-γ and IL-2 levels. The expression of H2-Eb1 mRNA and H2-Eb1 protein, as well as the ratio of GATA-3/T-bet expression, were upregulated in the nasal mucosa of the experimental group as compared to controls. CONCLUSION: H2-Eb1 expression, accompanied by an increased GATA-3/T-bet ratio were significantly upregulated in the nasal mucosa of our successfully established AR mouse model, suggesting that HLA-DRB1 may play an important role in the pathogenesis of AR and in Th1/Th2 balance regulation.
Asunto(s)
Cadenas HLA-DRB1/biosíntesis , Mucosa Nasal/metabolismo , Rinitis Alérgica/metabolismo , Células TH1/inmunología , Células Th2/inmunología , Animales , Western Blotting , Citocinas/biosíntesis , Citocinas/inmunología , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Femenino , Cadenas HLA-DRB1/inmunología , Inmunohistoquímica , Ratones , Mucosa Nasal/inmunología , Reacción en Cadena en Tiempo Real de la Polimerasa , Rinitis Alérgica/inmunología , Regulación hacia ArribaRESUMEN
Frequencies of human leucocyte antigens (HLA) were determined in 287 classic hairy cell leukaemia (HCL) patients. With respect to both population (n = 287) and allele (2n = 574) frequency respectively, the most common HLA class I and II antigens expressed were HLA-A*02 (49·1% and 28·6%), HLA-B*07 (21·3% and 11·1%), HLA-C*07 (46·7 and 28·2%), HLA-DQB1*03 (62·7% and 37·3%), HLA-DRB1*11 (30·0% and 16·0%) and HLA-DRB4*01 (45·3% and 29·6%). In comparing 6-14 databases of control Caucasians to 267 Caucasian HCL patients, only HLA-DRB1*11 was consistently over-represented in HCL, 31·1% of patients vs. 17-19·9% of controls (P = 0·0055 to <0·0001) and 16·5% of alleles vs. 6·5-12·3% of control alleles (P = 0·022 to <0·0001). HLA-DRB1*11 is a known risk factor for acquired thrombotic microangiopathy. Anti-CD22 recombinant immunotoxin BL22 in HCL was associated with a 12% incidence of completely reversible grade 3-4 haemolytic uraemic syndrome (HUS), mainly during the second or third retreatment cycle. Of 49 HCL patients receiving ≥2 cycles of BL22, 7 (14%) had HUS and HLA-DRB1*11 was expressed in 71% of 7 with HUS compared with only 21% of 42 without (P = 0·015). These data suggest that DBR1*11 may be a marker for increased susceptibility to HCL and, among HCL patients, could be a risk factor for BL22-induced HUS.
Asunto(s)
Cadenas HLA-DRB1/biosíntesis , Síndrome Hemolítico-Urémico/genética , Síndrome Hemolítico-Urémico/metabolismo , Leucemia de Células Pilosas/genética , Leucemia de Células Pilosas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Alelos , Toxinas Bacterianas/uso terapéutico , Exotoxinas/uso terapéutico , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Cadenas HLA-DRB1/genética , Cadenas HLA-DRB1/inmunología , Síndrome Hemolítico-Urémico/inmunología , Síndrome Hemolítico-Urémico/terapia , Humanos , Leucemia de Células Pilosas/inmunología , Leucemia de Células Pilosas/terapia , Masculino , Persona de Mediana Edad , Factores de Riesgo , Microangiopatías Trombóticas , Donantes de Tejidos , Adulto JovenRESUMEN
Using two microarray platforms, we identify HLA-DRB5 as the most highly expressed gene in MS compared to healthy subjects. As expected, HLA-DRB5 expression was associated with the HLA-DRB1*1501 MS susceptibility allele. Besides HLA-DRB5, there were 1219 differentially expressed exons (p<0.01, |fold change (FC)|>1.2) that differed between HLA-DRB1*1501 Positive multiple sclerosis subjects (MSP) compared to HLA-DRB1*1501 negative multiple sclerosis subjects (MSN). Analysis of the regulated genes revealed significantly different immune signaling pathways including IL-4 and IL-17 in these two MS genotypes. Different risk alleles appear to be associated with different patterns of gene expression that may reflect differences in pathophysiology of these two MS subtypes. These preliminary data will need to be confirmed in future studies.
Asunto(s)
Regulación de la Expresión Génica/inmunología , Predisposición Genética a la Enfermedad/genética , Estudio de Asociación del Genoma Completo/métodos , Genotipo , Cadenas HLA-DRB1/genética , Esclerosis Múltiple/genética , Adulto , Alelos , Femenino , Predisposición Genética a la Enfermedad/epidemiología , Cadenas HLA-DRB1/biosíntesis , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/diagnóstico , Esclerosis Múltiple/inmunología , Proyectos Piloto , Adulto JovenRESUMEN
Both genetic and environmental factors are implicated in type 1 diabetes (T1D). Because environmental factors can trigger epigenetic changes, we hypothesized that variations in histone post-translational modifications (PTMs) at the promoter/enhancer regions of T1D susceptible genes may be associated with T1D. We therefore evaluated histone PTM variations at known T1D susceptible genes in blood cells from T1D patients versus healthy nondiabetic controls, and explored their connections to T1D. We used the chromatin immunoprecipitation-linked to microarray approach to profile key histone PTMs, including H3-lysine 4 trimethylation (H3K4me3), H3K27me3, H3K9me3, H3K9 acetylation (H3K9Ac), and H4K16Ac at genes within the T1D susceptible loci in lymphocytes, and H3K4me3, H3K9me2, H3K9Ac, and H4K16Ac at the insulin-dependent diabetes mellitus 1 region in monocytes of T1D patients and healthy controls separately. We screened for potential variations in histone PTMs using computational methods to compare datasets from T1D and controls. Interestingly, we observed marked variations in H3K9Ac levels at the upstream regions of HLA-DRB1 and HLA-DQB1 within the insulin-dependent diabetes mellitus 1 locus in T1D monocytes relative to controls. Additional experiments with THP-1 monocytes demonstrated increased expression of HLA-DRB1 and HLA-DQB1 in response to interferon-γ and TNF-α treatment that were accompanied by changes in H3K9Ac at the same promoter regions as that seen in the patient monocytes. These results suggest that the H3K9Ac status of HLA-DRB1 and HLA-DQB1, two genes highly associated with T1D, may be relevant to their regulation and transcriptional response toward external stimuli. Thus, the promoter/enhancer architecture and chromatin status of key susceptible loci could be important determinants in their functional association to T1D susceptibility.
Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Epigénesis Genética , Predisposición Genética a la Enfermedad , Histonas/metabolismo , Procesamiento Proteico-Postraduccional , Diabetes Mellitus Tipo 1/genética , Femenino , Sitios Genéticos , Cadenas beta de HLA-DQ/biosíntesis , Cadenas beta de HLA-DQ/genética , Cadenas HLA-DRB1/biosíntesis , Cadenas HLA-DRB1/genética , Histonas/genética , Humanos , MasculinoRESUMEN
Lapatinib is a clinically important component of the treatment for HER2-positive metastatic breast cancer and has an acceptable safety profile. Lapatinib-associated Hy's Law cases have been characterized using human leukocyte antigen (HLA) DQA1*02:01/DRB1*07:01 and Gilbert's syndrome UGT1A1*28/*28 genotypes. The HLA-positive cases had higher alanine aminotransferase (ALT) elevation, whereas the HLA-negative cases had a higher incidence of Gilbert's syndrome. The findings of our study, which extend this HLA association to lapatinib-associated serious liver injury, emphasize the importance of Gilbert's syndrome in the interpretation of Hy's Law and may lead to methods for enhancing patient safety.